logo

For the Inventor, By the Inventor

Nijmegen, Netherlands

Synthon Biopharmaceuticals B.v.

Calculating rank
USPTO Granted Patents = 11

% Expired Patents = 27.3



Trademarks = 18

Forward Citations = 64

Loading Chart...
Loading Chart...

26 inventors (with patents filed for the assignee):

goldMedal Peter Johannes Goedings (4 out of 5 patents)

silverMedal Patrick Henry Beusker (3 out of 14 patents)

bronzeMedal Rudy Gerardus Elisabeth Coumans (3 out of 16 patents)

4.  Gerardus Joseph Andreas Ariaans (3 out of 8 patents)

5.  Willem Dokter (2 out of 3 patents)

6.  Gijsbertus Franciscus Maria Verheijden (2 out of 6 patents)

7.  Declan Thomas Nolan (2 out of 2 patents)

8.  Frans Van Dalen (2 out of 11 patents)

9.  Alessandro D Santin (2 out of 19 patents)

10.  Ronald Christiaan Elgersma (1 out of 6 patents)

11.  Johannes Albertus Frederikus Joosten (1 out of 8 patents)

12.  Henri Johannes Spijker (1 out of 9 patents)

13.  Franciscus Marinus Hendrikus De Groot (1 out of 11 patents)

14.  Guy De Roo (1 out of 1 patent)

15.  Ruud Martin Verstegen (1 out of 1 patent)


11 patents:

1. 10603387 - Duocarmycin ADCs showing improved in vivo antitumor activity (2020-03-31),
2. 10407743 - Site-specific conjugation of linker drugs to antibodies and resulting ADCs (2019-09-10),
3. 10266606 - Method for purifying Cys-linked antibody-drug conjugates (2019-04-23),
4. 10092659 - Duocarmycin ADCs for use in treatment of endometrial cancer (2018-10-09),
5. 9890159 - Process for making duocarmycin prodrugs (2018-02-13),
6. 9845338 - Method of purifying an antibody (2017-12-19),
7. 9580501 - Anti-TNF alpha monoclonal secretory IgA antibodies and methods for treating inflammatory diseases (2017-02-28),
8. 9573996 - Monoclonal antibodies to human proinflammatory cytokines and methods for treating inflammatory diseases (2017-02-21),
9. 9427480 - Duocarmycin ADCs for use in treatment of endometrial cancer (2016-08-30),
10. 9421278 - Duocarmycin ADCS showing improved in vivo antitumor activity (2016-08-23),
11. 8716557 - Compositions and methods for inhibition of fucosyltransferase and xylosyltransferase expression in plants (2014-05-06),
Company Overview
Synthon Biopharmaceuticals B.V. is a biopharmaceutical company based in Nijmegen, Netherlands, specializing in the development and manufacturing of complex generic and specialty pharmaceuticals. The organization focuses on innovative drug delivery systems and biosimilars, leveraging advanced technologies to enhance therapeutic options. With a commitment to improving patient outcomes, Synthon collaborates with various stakeholders in the healthcare sector to bring high-quality, affordable medicines to market, addressing unmet medical needs globally.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

11 Patents

#6 in Nijmegen

#569 in Netherlands

#51,831 in the World

Nijmegen, NL
Nijmegen, Netherlands

Synthon Biopharmaceuticals B.v.

Forward Citations = 64

26 inventors:

goldMedal Peter Johannes Goedings (4 out of 5 patents)

silverMedal Patrick Henry Beusker (3 out of 14 patents)

bronzeMedal Rudy Gerardus Elisabeth Coumans (3 out of 16 patents)

4.  Gerardus Joseph Andreas Ariaans (3 out of 8 patents)

5.  Willem Dokter (2 out of 3 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Synthon Biopharmaceuticals B.v.. Retrieved from https://idiyas.com/company/synthon-biopharmaceuticals-b-v

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…